Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

被引：0
|
作者：
Flinn, Ian W.
Gribben, John G.
Dyer, Martin J. S.
Wierda, William G.
Maris, Michael B.
Furman, Richard R.
Hillmen, Peter
Jones, Jeffrey
Iyer, Swami P.
Jones, Surai
Jiang, Yanwen
Pignataro, Daniela Soriano
Humphrey, Kathryn
Mobasher, Mehrdad
Kipps, Thomas J.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
430
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)
    Flinn, Ian W.
    Brunvand, Mark
    Choi, Michael Y.
    Dyer, Martin J. S.
    Gribben, John
    Hillmen, Peter
    Jones, Jeffrey
    Li, Yan
    Mobasher, Mehrdad
    Vosganian, Gregory
    Kipps, Thomas J.
    BLOOD, 2015, 126 (23)
  • [2] Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
    Flinn, Ian
    Brunvand, Mark
    Dyer, Martin J. S.
    Hillman, Peter
    Jones, Jeffrey
    Lymp, James
    Elhamy, Mostafa
    Vosganian, Gregory
    Huang, Jane
    Kipps, Thomas J.
    BLOOD, 2014, 124 (21)
  • [3] Preliminary Safety and Efficacy Results From a Phase 2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
    Awan, Farrukh T.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 6 - 8
  • [4] Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
    Flinn, Ian W.
    Gribben, John G.
    Dyer, Martin J. S.
    Wierda, William
    Maris, Michael B.
    Furman, Richard R.
    Hillmen, Peter
    Rogers, Kerry A.
    Iyer, Swaminathan Padmanabhan
    Quillet-Mary, Anne
    Ysebaert, Loic
    Walter, Harriet S.
    Verdugo, Maria
    Klein, Christian
    Huang, Huang
    Jiang, Yanwen
    Lozanski, Gerard
    Pignataro, Daniela Soriano
    Humphrey, Kathryn
    Mobasher, Mehrdad
    Kipps, Thomas J.
    BLOOD, 2019, 133 (26) : 2765 - 2775
  • [5] Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Lampson, Benjamin L.
    Tyekucheva, Svitlana
    Crombie, Jennifer L.
    Kim, Austin I.
    Merryman, Reid W.
    Lowney, Jessica
    Montegaard, Josie
    Patterson, Victoria
    Jacobson, Caron A.
    Jacobsen, Eric D.
    LaCasce, Ann S.
    Arnason, Jon E.
    Armand, Philippe
    Fisher, David C.
    Brown, Jennifer R.
    Davids, Matthew S.
    BLOOD, 2019, 134
  • [6] Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia
    Rogers, Kerry A.
    Huang, Ying
    Ruppert, Amy S.
    Awan, Farrukh T.
    Heerema, Nyla A.
    Hoffman, Corinne
    Lozanski, Gerard
    Maddocks, Kami J.
    Moran, Mollie E.
    Reid, Mark A.
    Lucas, Margaret
    Woyach, Jennifer A.
    Whitlow, W. Thomas
    Jones, Jeffrey A.
    Byrd, John C.
    BLOOD, 2018, 132 (15) : 1568 - 1572
  • [7] Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440)
    Stilgenbauer, Stephan
    Morschhauser, Franck
    Wendtner, Clemens-Martin
    Cartron, Guillaume
    Hallek, Michael
    Eichhorst, Barbara
    Kozloff, Mark F.
    Giever, Thomas
    Lozanski, Gerard
    Jiang, Yanwen
    Huang, Huang
    Pignataro, Daniela Soriano
    Schary, William
    Humphrey, Kathryn
    Mobasher, Mehrdad
    Salles, Gilles
    BLOOD, 2018, 132
  • [8] A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
    Christine E. Ryan
    Danielle M. Brander
    Paul M. Barr
    Svitlana Tyekucheva
    Liam R. Hackett
    Mary C. Collins
    Stacey M. Fernandes
    Yue Ren
    Yinglu Zhou
    Mikaela M. McDonough
    Heather A. Walker
    Monica R. McEwan
    Jeremy S. Abramson
    Eric D. Jacobsen
    Ann S. LaCasce
    David C. Fisher
    Jennifer R. Brown
    Matthew S. Davids
    Leukemia, 2023, 37 : 835 - 842
  • [9] A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
    Ryan, Christine E.
    Brander, Danielle M.
    Barr, Paul M.
    Tyekucheva, Svitlana
    Hackett, Liam R.
    Collins, Mary C.
    Fernandes, Stacey M.
    Ren, Yue
    Zhou, Yinglu
    McDonough, Mikaela M.
    Walker, Heather A.
    McEwan, Monica R.
    Abramson, Jeremy S.
    Jacobsen, Eric D.
    LaCasce, Ann S.
    Fisher, David C.
    Brown, Jennifer R.
    Davids, Matthew S.
    LEUKEMIA, 2023, 37 (04) : 835 - 842
  • [10] The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia
    Al-Sawaf, Othman
    Fuerstenau, Moritz
    Giza, Adam
    Robrecht, Sandra
    Von Tresckow, Julia
    Fink, Anna Maria
    Simon, Florian
    Tausch, Eugen
    Schneider, Christof
    Sivcheva, Liliya
    Schwarer, Anthony
    Loscertales, Javier
    Weinkove, Robert
    Strumberg, Dirk
    Kilfoyle, Allanah R.
    Juliusson, Gunnar
    Da Cunha-Bang, Caspar
    Illmer, Thomas
    Gregor, Michael
    Thornton, Patrick
    Janssens, Ann
    Tadmor, Tamar
    Lindstrom, Vesa
    Staber, Philipp Bernhard
    Levin, Mark-David
    Wendtner, Clemens-Martin
    Kreuzer, Karl-Anton
    Ritgen, Matthias
    Stilgenbauer, Stephan
    Kater, Arnon P.
    Niemann, Carsten Utoft
    Fischer, Kirsten
    Eichhorst, Barbara F.
    Hallek, Michael
    BLOOD, 2023, 142
12345